Thrombolex Inc.

Founded in 2016, Thrombolex, Inc. is engaged in the design, development, manufacture and distribution of innovative endovascular catheters.

06/18/2026

In PE care, what happens after the procedure matters as much as what happens during it.

Single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device is designed to support targeted clot fragmentation and thrombolytic delivery in a structured, efficient intervention, without the need for post-procedure infusion. Clinical experience has demonstrated no major bleeding events in the reported cohort, supporting a pathway that reduces intensive care utilization and total length of hospital stay.

For institutions managing acute PE patients, that kind of post-procedure efficiency is not incidental. It is part of what makes a clinically proven solution worth choosing.

Thrombolex.com

06/15/2026

A strong PERT program depends on having reliable, consistent tools that fit the way your team works.

The BASHIR® Endovascular Device is a standalone technology that requires no capital equipment and integrates into existing lab workflows across a broad range of healthcare facilities. Designed to support single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML), it gives PERT teams a targeted, clinically proven solution that delivers procedural consistency and clinical confidence, without adding complexity to an already demanding care environment.

Thrombolex.com

06/12/2026

The BASHIR® Endovascular Device's expandable infusion basket is engineered for mechanical fragmentation along with uniform delivery of thrombolytics to the segmental branches of the pulmonary arteries, creating focused pharmacologic exposure precisely where clot burden is greatest. This integrated approach supports a controlled, structured intervention that maintains procedural consistency from the first step to the last.

It is not just about where the therapy goes. It is about how reliably it gets there.

Thrombolex.com

06/09/2026

Not all venous thrombus presents in the same way, and not all devices are built to address that variability.

The BASHIR® Plus Endovascular Device is designed for the treatment of venous thrombus with extensive clot burden, offering variable shaft infusion lengths - available in +10, +20, +30, and +40 configurations - to support mechanical fragmentation along with targeted uniform thrombolytic delivery across a range of anatomical presentations. The expandable infusion basket enables precise pharmaco-mechanical lysis without the need for capital equipment, making it straightforward to integrate into existing lab workflows.

Thrombolex.com

06/04/2026

The evidence for single-session PML continues to grow.

Interim data from the first 50 patients in the RAPID-PE Study - a prospective, multicenter U.S. study evaluating on-the-table (OTT) pharmaco-mechanical lysis (PML) - was presented at TCT 2025. The analysis demonstrated that on-the-table PML using the BASHIR® Endovascular Device can be performed efficiently and without post-procedure infusion, offering the interventional community meaningful insight into what structured, targeted PE intervention looks like in practice.

As the study continues to enroll, the RAPID-PE Study reinforces the clinical case for single-session care in acute PE treatment.

Learn more at Thrombolex.com.

06/02/2026

The results of the RESCUE-II Study have been published in JACC: Advances, and the data speaks for itself.

This peer-reviewed publication validates the role of the BASHIR® Endovascular Device as a clinically proven solution in the treatment of A&VTE, demonstrating significant reductions in RV/LV ratio and PA obstruction with no major bleeding events and no requirement for post-procedure infusion. All achieved in a single, on-the-table (OTT) pharmaco-mechanical lysis (PML) session.

In PE care, clinical confidence is earned through evidence. The RESCUE-II Study delivers exactly that.

Read the full publication in JACC: Advances at Thrombolex.com.

05/31/2026

Clinical confidence is built on evidence, and the RESCUE-II Study delivers.

In the RESCUE-II Study, patients treated with the BASHIR® Endovascular Device for acute pulmonary embolism demonstrated significant reductions in RV/LV ratio and PA obstruction, with no major bleeding events and no requirement for post-procedure infusion - all in a single session.

Learn more here: https://www.jacc.org/doi/10.1016/j.jacadv.2025.101789

Thrombolex.com

05/29/2026

When treating pulmonary embolism, focus matters at every step.

The BASHIR® Endovascular Device is designed to support targeted thrombolytic delivery and mechanical clot fragmentation, helping clinicians maintain procedural consistency and clinical confidence throughout a single, on-the-table (OTT) pharmaco-mechanical lysis (PML) session.

Thrombolex.com

05/27/2026

Evidence-based medicine is not a preference in pulmonary embolism treatment. It is a responsibility. Every clinical choice - the approach, the therapy, the protocol - shapes what happens next for the patient.

Choosing a therapy that is safe, reliable, and supported by clinical data matters because the outcomes on the other side of that decision belong to a real person. That's why Thrombolex invests in the clinical programs, resources, and a Family of Endovascular Devices that give the interventional community the evidence and tools they need to deliver better outcomes for every patient.

Thrombolex.com

05/25/2026

On Memorial Day, we pause to honor the brave men and women who gave their lives in service to our country. Their sacrifice inspires what we do - advancing care that helps save lives every day.

Thrombolex.com

Address

75 Britain Drive
New Britain, PA
18901

Telephone

+18447926300

Website

http://www.thrombolex.com/

Alerts

Be the first to know and let us send you an email when Thrombolex Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Thrombolex Inc.:

Shortcuts

Want your business to be the top-listed Health & Beauty Business in New Britain?